Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 8:9:F1000 Faculty Rev-686.
doi: 10.12688/f1000research.22662.1. eCollection 2020.

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin

Filippo Caraci  1   2 , Mario Santagati  3 , Giuseppe Caruso  2 , Dario Cannavò  3 , Gian Marco Leggio  4 , Salvatore Salomone  4 , Filippo Drago  4
Affiliations
Review

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin

Filippo Caraci et al. F1000Res. .

Abstract

Behavioral and psychological symptoms of dementia are symptoms of disturbed perception, mood, behavior, and thought content that occurred frequently. These symptoms, which include apathy, depression, anxiety, psychosis, agitation, and aggression, can serve as predictors of and early clinical diagnostic markers for Alzheimer's disease (AD) and are common precipitants of institutional care. Agitation and psychosis are associated with accelerated disease progression and increased tau phosphorylation in patients with AD. Current guidelines recommend the use of second-generation antipsychotics for the treatment of agitation and psychosis in AD, but only after first-line non-pharmacological interventions and for no longer than 12 weeks because long-term use of these drugs is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. Therefore, new antipsychotic drugs with improved efficacy and safety are needed as an alternative to current antipsychotic drugs. In this report, we discuss some of the most relevant advances in the field of agitation and psychosis in AD and focus on the recent positive clinical evidence observed with two new antipsychotics drugs: brexpiprazole and pimavanserin. Brexpiprazole is a receptor partial agonist (D2, D3, 5-HT1A), receptor antagonist (5-HT2A/B, α1B/α2C) according to the neuroscience-based nomenclature. Two recent phase III clinical trials have shown that brexpiprazole 2 mg/day is effective for the treatment of agitation in patients with AD and has an improved tolerability and safety profile compared with currently available second-generation antipsychotics. Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson's disease. Recent phase II studies suggest that this drug is effective in AD patients with more severe psychosis, although further long-term studies are needed to better define the efficacy and long-term safety profile of pimavanserin for the treatment of psychosis in AD.

Keywords: Alzheimer’s disease; agitation; brexpiprazole; pimavanserin; psychosis; second-generation antipsychotics.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Prince M, Guerchet M, Prina M: Policy Brief for Heads of Government: The Global Impact of Dementia 2013–2050. London: Alzheimer's Disease International (ADI);2013; [cited 2013 Dec 20]. Reference Source
    1. Prince M, Wimo A, Guerchet M, et al. : Alzheimer’s Disease International: World Alzheimer Report 2015: The Global Impact of Dementia: an Analysis of Prevalence, Incidence, Cost and Trends. 2015. Alzheimer’s Disease International: London.2019. Reference Source
    1. Bessey LJ, Walaszek A: Management of Behavioral and Psychological Symptoms of Dementia. Curr Psychiatry Rep. 2019;21(8):66. 10.1007/s11920-019-1049-5 - DOI - PubMed

    2. Faculty Opinions Recommendation

    1. Beeri MS, Werner P, Davidson M, et al. : The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry. 2002;17(5):403–8. 10.1002/gps.490 - DOI - PubMed
    1. Peters ME, Schwartz S, Han D, et al. : Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: The Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460–5. 10.1176/appi.ajp.2014.14040480 - DOI - PMC - PubMed